Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 November 2021Website:
http://www.cero.bioNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
CERO Latest News
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich.
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes
What type of business is CERo Therapeutics Holdings?
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
What sector is CERo Therapeutics Holdings in?
CERo Therapeutics Holdings is in the Healthcare sector
What industry is CERo Therapeutics Holdings in?
CERo Therapeutics Holdings is in the Biotechnology industry
What country is CERo Therapeutics Holdings from?
CERo Therapeutics Holdings is headquartered in United States
When did CERo Therapeutics Holdings go public?
CERo Therapeutics Holdings initial public offering (IPO) was on 30 November 2021
What is CERo Therapeutics Holdings website?
https://www.cero.bio
Is CERo Therapeutics Holdings in the S&P 500?
No, CERo Therapeutics Holdings is not included in the S&P 500 index
Is CERo Therapeutics Holdings in the NASDAQ 100?
No, CERo Therapeutics Holdings is not included in the NASDAQ 100 index
Is CERo Therapeutics Holdings in the Dow Jones?
No, CERo Therapeutics Holdings is not included in the Dow Jones index
When was CERo Therapeutics Holdings the previous earnings report?
No data
When does CERo Therapeutics Holdings earnings report?
Next earnings report date is not announced yet